Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level
- 12 November 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death & Differentiation
- Vol. 18 (4), 700-711
- https://doi.org/10.1038/cdd.2010.144
Abstract
TNF-related apoptosis-inducing ligand or Apo2L (Apo2L/TRAIL) is a promising anti-cancer drug owing to its ability to trigger apoptosis by binding to TRAIL-R1 or TRAIL-R2, two membrane-bound receptors that are often expressed by tumor cells. TRAIL can also bind non-functional receptors such as TRAIL-R4, but controversies still exist regarding their potential to inhibit TRAIL-induced apoptosis. We show here that TRAIL-R4, expressed either endogenously or ectopically, inhibits TRAIL-induced apoptosis. Interestingly, the combination of chemotherapeutic drugs with TRAIL restores tumor cell sensitivity to apoptosis in TRAIL-R4-expressing cells. This sensitization, which mainly occurs at the death-inducing signaling complex (DISC) level, through enhanced caspase-8 recruitment and activation, is compromised by c-FLIP expression and is independent of the mitochondria. Importantly, TRAIL-R4 expression prevents TRAIL-induced tumor regression in nude mice, but tumor regression induced by TRAIL can be restored with chemotherapy. Our results clearly support a negative regulatory function for TRAIL-R4 in controlling TRAIL signaling, and unveil the ability of TRAIL-R4 to cooperate with c-FLIP to inhibit TRAIL-induced cell death.Keywords
This publication has 39 references indexed in Scilit:
- Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cellsEuropean Journal of Cancer, 2010
- Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancerJournal of Molecular Medicine, 2009
- Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosisNature, 2009
- Oxaliplatin enhances TRAIL‐induced apoptosis in gastric cancer cells by CBL‐regulated death receptor redistribution in lipid raftsFEBS Letters, 2009
- Bid Participates in Genotoxic Drug-Induced Apoptosis of HeLa Cells and Is Essential for Death Receptor Ligands' Apoptotic and Synergistic EffectsPLOS ONE, 2008
- TRAIL in cancer therapy: present and future challengesEmerging Therapeutic Targets, 2007
- Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platformsApoptosis, 2007
- Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2Molecular and Cellular Biology, 2006
- Expression of TRAIL (TNF‐related apoptosis‐inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomasThe Journal of Pathology, 2003